News &amp; Updates

Among patients with lung squamous cell carcinoma (LUSC), lower levels of high-density lipoprotein cholesterol (HDL-C) appear to aggravate the risk of worse outcomes, a recent study has found.

Lipid profile tied to outcomes in lung squamous cell carcinoma

Adjuvant FOLFIRINOX ups survival in pancreatic cancer

15 Oct 2022 by

Adjuvant chemotherapy with a modified dose of FOLFIRINOX (mFOLFIRINOX) was associated with significantly better survival outcomes, particularly disease-free survival (DFS) and overall survival (OS), compared with single-agent gemcitabine in patients with resected pancreatic ductal adenocarcinoma (PDAC), according to a 5-year analysis of the PRODIGE 24/Canadian Cancer Trials Group PA6* study.

Adjuvant FOLFIRINOX ups survival in pancreatic cancer

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

New drug applications approved by US FDA as of 01 - 15 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

Updated BEST results: No major difference between EES or CABG for multivessel disease

In patients with multivessel coronary artery disease, the risk of any-cause death, myocardial infarction (MI), or target vessel revascularization (TVR) did not vary according to whether patients underwent percutaneous coronary intervention (PCI) with everolimus-eluting stents (EES) or coronary artery bypass graft (CABG), extended follow-up of the BEST* trial showed.

Updated BEST results: No major difference between EES or CABG for multivessel disease

Pre-DAA IL-1β can predict HBV reactivation in HCV

Among hepatitis C virus (HCV) patients with resolved hepatitis B virus (HBV) infections, levels of interleukin (IL)-1β before the initiation of direct-acting antiviral (DAA) treatment may help predict HBV reactivation, reports a recent study.

Pre-DAA IL-1β can predict HBV reactivation in HCV

14 Oct 2022

DIY diabetes management with digital app facilitates better weight, blood sugar control

Self-management of diabetes through smartphone heath app engagement appears to bring positive changes in disease outcomes such as weight and blood sugar, according to data from the Diabetes Lifestyle Intervention using Technology Empowerment (D’LITE) study.

DIY diabetes management with digital app facilitates better weight, blood sugar control

14 Oct 2022

Dexmedetomidine-related fever seen in some adult ICU patients

A few patients in the intensive care unit (ICU) have registered a fever >38.5 °C while on dexmedetomidine therapy, reports a recent study.

Dexmedetomidine-related fever seen in some adult ICU patients

Maternal ultra-processed food intake ups risk of childhood obesity

Mothers who regularly eat ultra-processed foods during the child-rearing period appear to increase the risk of overweight or obesity in their children, irrespective of maternal and offspring lifestyle risk factors, a study has shown.

Maternal ultra-processed food intake ups risk of childhood obesity

14 Oct 2022

Fluoroquinolone reduction initiative lowers antibiotic use, resistance

A nonrestrictive fluoroquinolone reduction initiative at an urban teaching hospital has substantially lessened the use of this drug, which is associated with decreased antibiotic resistance in Staphylococcus aureus and Pseudomonas aeruginosa, a study has shown.

Fluoroquinolone reduction initiative lowers antibiotic use, resistance

Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC